Fasting

Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes

Retrieved on: 
Mercredi, novembre 8, 2023
INAF, Meal, Research, Trial of the century, Faculty, Fasting, Stomach, Peptide YY, Endocrine gland, Membrane protein, GIP, Human, Regulatory News Service, Université Laval, Hyperinsulinemia, Agonal respiration, PYY, Type 2 diabetes, Inflammation, Fibrinogen, Metabolism, Volunteering, Development, Glycated hemoglobin, Phase, Prediabetes, Food court, Lipid, Disease, Risk, Plant, Medicine, Research and development, Faculty of Medicine, King Mongkut's Institute of Technology Ladkrabang, Medical school, Industrial Affairs Committee (Iceland), Partnership, Sensation, Blood, Nutrition, Hormone, CET, Safety, Insulin resistance, Overweight, Gastric inhibitory polypeptide, Glucose, Insulin, Pharmaceutical industry, Dietary supplement, Medical device, Animal feed

Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes

Key Points: 
  • Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The study confirms TOTUM•63's efficacy results, in particular the lasting reduction in glycated hemoglobin, one of the main markers of prediabetes and type 2 diabetes.
  • It demonstrates TOTUM•63's multi-target mode of action in subjects at risk, improving the efficacy of energy metabolism, particularly after meals.
  • Mode of action clinical results: TOTUM•63 regulates energy metabolism
    In addition to the positive clinical efficacy studies already conducted, the mode of action study was carried out on 19 overweight or obese volunteers at risk of developing type 2 diabetes.

Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®

Retrieved on: 
Jeudi, novembre 2, 2023
CORAL, Fasting, Patent, Rare, United States Patent and Trademark Office, Orange Book, Catalyst Pharmaceuticals, Amifampridine, Approved Drug Products with Therapeutic Equivalence Evaluations, Lambert–Eaton myasthenic syndrome, Tablet, Patient, NAT2, Pharmaceutical industry, Catalysis

FIRDAPSE is the only approved treatment available in the U.S. for Lambert-Eaton myasthenic syndrome.

Key Points: 
  • FIRDAPSE is the only approved treatment available in the U.S. for Lambert-Eaton myasthenic syndrome.
  • "We are very pleased to receive these patent notifications from the USPTO.
  • "These patent allowances strengthen our cumulative understanding of the uniqueness of FIRDAPSE and bolster its strong intellectual property estate offering enhanced patent protection," stated Dr. Steven Miller, Chief Operating Officer and Chief Scientific Officer of Catalyst.
  • Preparations are already in motion to include these additional FIRDAPSE patents in the FDA Orange Book post-grant, bringing the total listed patent count to eight."

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)

Retrieved on: 
Vendredi, octobre 20, 2023
FDA, Fasting, Headache, Minocycline, Rosacea, Food, Abbreviated New Drug Application, Conference, Entrepreneurship, Pharmacokinetics, Male, Marketing, Safety, Patient, Generic drug, Pharmaceutical industry

SCOTTSDALE, Ariz., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced data from a comparative bioavailability (bridging) study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg). DFD-29 is being developed for the treatment of rosacea in collaboration with Dr. Reddy’s Laboratories Ltd. The data were presented at the 43rd Annual Fall Clinical Dermatology Conference taking place in Las Vegas, NV.

Key Points: 
  • DFD-29 is being developed for the treatment of rosacea in collaboration with Dr. Reddy’s Laboratories Ltd.
  • The data were presented at the 43rd Annual Fall Clinical Dermatology Conference taking place in Las Vegas, NV.
  • “The results of this bioavailability study successfully demonstrate that the systemic exposure of minocycline with DFD-29 (40 mg) was significantly lower than that of Solodyn (105 mg),” said Srinivas Sidgiddi, M.D., Vice President, Research & Development of Journey Medical.
  • Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical, stated, “We continue to be encouraged by the growing body of clinical research evaluating DFD-29.

Lifesum unveils Healthy Fasting Program to increase employee wellbeing and optimize productivity

Retrieved on: 
Mardi, octobre 24, 2023
PayPal, Eating, Fasting, GE, Amazon, Feedback, Organization, Health, Research, Food, Mental health, Food delivery, Nursing, Dietary supplement

LOS ANGELES, Oct. 24, 2023 /PRNewswire/ -- Lifesum , the leading global healthy eating platform, used by companies, including Amazon, GE and PayPal to improve workplace wellness, has unveiled a healthy fasting program to help employees increase wellbeing and optimize productivity.

Key Points: 
  • LOS ANGELES, Oct. 24, 2023 /PRNewswire/ -- Lifesum , the leading global healthy eating platform, used by companies, including Amazon, GE and PayPal to improve workplace wellness, has unveiled a healthy fasting program to help employees increase wellbeing and optimize productivity.
  • Unlike other fasting programs, Lifesum's Healthy Fasting Program offers a safe, sustainable fasting experience tailored to individual needs.
  • At Lifesum, our Healthy Fasting Program, combined with nutritional expertize and guidance found in the Lifesum app, provides employees with a holistic, sustainable fasting experience tailored to their individual needs for optimal wellbeing," said Signe Svanfeldt, Lifesum Lead Nutritionist.
  • "The Healthy Fasting Program is further evidence of Lifesum improving workplace wellbeing by enabling people and the organizations they work for to access best-in-class consumer technology," added Svanfeldt.

Mimio Health Commercially Launches Groundbreaking Biomimetic Based on the Science of Fasting to Promote Cellular Health and Longevity

Retrieved on: 
Jeudi, octobre 19, 2023
Science, University of California, Davis, Fasting, Ageing, Health, UC, Motivation, PEA, Autophagy, Spermidine, Research, Nature, OEA, The American Journal of Clinical Nutrition, Biology, SAN, Biomimetics, SOSV, American Journal, Cognition, Longevity, Mobile phone, Pharmaceutical industry, Dietary supplement, Mimio

SAN FRANCISCO, Oct. 19, 2023 /PRNewswire-PRWeb/ -- Mimio Health, the biomimetic human health company, announced today the commercial launch of their flagship product, Mimio. Mimio is a biomimetic designed from human biology to unlock the cellular health and longevity benefits of long-term fasting, without needing to fast. By upregulating and enhancing these cellular processes, Mimio supercharges the body's natural restorative abilities.

Key Points: 
  • Mimio is a biomimetic designed from human biology to unlock the cellular health and longevity benefits of long-term fasting, without needing to fast.
  • Mimio is a biomimetic designed from human biology to unlock the cellular health and longevity benefits of long-term fasting, without needing to fast.
  • Fasting has been shown across thousands of studies to be one of the most powerful ways to enhance health and promote longevity.
  • Using fasting as a roadmap, Mimio Health's biomimetic research has studied and decoded the changes that happen in the body to activate this innate longevity bio-program.

Man, 69, Pens Book About His and Others' Near Perfect Bodies

Retrieved on: 
Mardi, octobre 17, 2023
Food, Health, Teaching, Diet, WEST, Weight loss, PGA, Rehabilitation, Fasting, PALM, Hunting, Financial adviser, Birth control, Book

WEST PALM BEACH, Fla., Oct. 16, 2023 /PRNewswire/ -- What happens when a fat cat financial pro wants to ditch the fat for a near perfect body?

Key Points: 
  • WEST PALM BEACH, Fla., Oct. 16, 2023 /PRNewswire/ -- What happens when a fat cat financial pro wants to ditch the fat for a near perfect body?
  • "Losing weight and looking great is better fought with the mind than the body, and that's what I am teaching."
  • Moving away from a perfect body, which is impossible to achieve in any event, to a near perfect body, which is very possible to achieve, Shorr says, changed everything.
  • "While I wrote this book originally to explain what I discovered about the journey to a near perfect body, the lessons can apply to nearly any goal readers want to achieve," Shorr added.

Cytoki Pharma Presents Preclinical Data Demonstrating Weight Reduction and Improved Glucose Control with Lipidated IL-22 at ObesityWeek 2023

Retrieved on: 
Lundi, octobre 16, 2023
DIO, Pharmacokinetics, Obesity, Biology, Weight loss, Liver, Diabetes, DSM-IV codes, Safety, Administration, Human, Anpartsselskab, SC, Fasting, Lipid metabolism, Mouse, Phase 1, Glycated hemoglobin, Quality of life, Pharmaceutical industry

COPENHAGEN, Denmark, Oct. 16, 2023 /PRNewswire/ -- Cytoki Pharma, ApS (Cytoki), a clinical-stage biotechnology company pioneering a new class of medicines that harness IL-22 biology to drive improved outcomes for metabolic disease, today presented preclinical data demonstrating the potential of lipidated IL-22 to induce weight loss and positively impact a range of cardiometabolic risk factors at ObesityWeek 2023, held October 14-17 in Dallas.

Key Points: 
  • IL-22 is an atypical, non-immunomodulatory cytokine, which selectively targets epithelial tissues, including those that play important roles in metabolic processes, such as the gut and liver.
  • Cytoki's lipidated IL-22 analogues leverage this innate biology and offer first-in-class potential to address a range of metabolic diseases, including obesity and type 2 diabetes.
  • Subsequent studies in diabetic db/db mice indicate that treatment with lipidated IL-22 normalized blood glucose levels and reduced HbA1c levels independent of food intake, accompanied by dose-dependent insulin sensitization.
  • The presentation details are as follows:
    Location: Kay Bailey Hutchinson Convention Center, Room D174

Discover the Power of Fasting for Health and Longevity at The Fasting & Longevity Summit Taking Place from January 2-8, 2024

Retrieved on: 
Mardi, septembre 26, 2023
MPP, DNM, Quality of life, Fasting, Longevity, Inflammation, Doctor of Philosophy, MS, Intermittent fasting, Conditional sentence, Knowledge, Health, MD

CARLSBAD, Calif., Sept. 26, 2023 /PRNewswire/ -- DrTalks is thrilled to announce the upcoming Fasting & Longevity Summit. This transformative online event will provide attendees with the tools and knowledge needed to harness the power of fasting for improved healthspan and reduced inflammation. Taking place from January 2 - 8, 2024, this free virtual summit is open to anyone wishing to explore fasting as a life-enhancing practice.

Key Points: 
  • Fasting experts Joseph Antoun, MD, PhD, MPP, and Dr. David Jockers, DNM, DC, MS, will teach you how to fast safely and effectively to improve your health at The Fasting & Longevity Summit.
  • The Fasting & Longevity Summit explores the benefits of ancient fasting practices, guiding participants toward enhanced vitality and combating chronic diseases.
  • CARLSBAD, Calif., Sept. 26, 2023 /PRNewswire/ -- DrTalks is thrilled to announce the upcoming Fasting & Longevity Summit .
  • Taking place from January 2 - 8, 2024, this free virtual summit is open to anyone wishing to explore fasting as a life-enhancing practice.

US Physicians Name Two Weight Loss Drugs as “Paradigm-Shifting,” While Cautioning on Safety and Cost, According to New InCrowd Report

Retrieved on: 
Mardi, septembre 19, 2023
Diabetes, Fitness & Nutrition, Clinical Trials, Cardiology, Practice Management, Other Health, Biotechnology, Managed Care, Pharmaceutical, Health, Exercise, Semaglutide, Insurance, PCP, Public, Weight loss, CDC, Patient, Physician, Overweight, American Association of Clinical Endocrinologists, Fasting, Safety, Pharmaceutical industry, Nursing, Dietary supplement, Liraglutide

Data are from InCrowd , a real-time global data and insights provider to the healthcare and life sciences industry, and a brand of Apollo Intelligence (Apollo).

Key Points: 
  • Data are from InCrowd , a real-time global data and insights provider to the healthcare and life sciences industry, and a brand of Apollo Intelligence (Apollo).
  • Among weight loss drugs, doctors had the highest clinical familiarity with semaglutide (96%) as well with liraglutide, sold as Saxenda and Victosa (94%) in addition to tirzepatide (87%).
  • New medications in the market have shown wonderful response to therapeutic weight loss management with minimal side effects.
  • Each respondent has treated 20+ weight loss patients in the past month and prescribes prescription medications for weight loss.

Intermittent Fasting Effects on Memory & Focus: New Report by FastingFuelHQ

Retrieved on: 
Jeudi, septembre 14, 2023
Cognition, Exercise, Meditation, Student, Fasting, Health, Ketone, Mindfulness, Fast food

FastingFuelHQ has released a report outlining the correlation between intermittent fasting, brain function, and memory, aimed at college students who seek to access their full academic potential through diet and lifestyle changes.

Key Points: 
  • Fresno, California--(Newsfile Corp. - September 14, 2023) - FastingFuelHQ's new report was written for university students who wish to learn more about the potential benefits of intermittent fasting and the ways it can affect focus and energy levels while studying.
  • Intermittent Fasting Effects On Memory & Focus: New Report By FastingFuelHQ
    To view an enhanced version of this graphic, please visit:
    As intermittent fasting becomes increasingly popular as a method to improve overall health and energy levels, the report from FastingFuelHQ outlines some current academic studies in this growing area of interest, while also offering practical tips and techniques for students who wish to try intermittent fasting for themselves.
  • FastingFuelHQ also has a guide which helps to align an intermittent fasting protocol with a busy student lifestyle, including an explanation of different fasting windows, such as the 16/8 method or Eat-Stop-Eat approach, alongside a discussion of the respective benefits and drawbacks for each plan.
  • Additional tips and tools for successful fasting are included in the report - including the importance of hydration and good sleep, healthy ways to break a fast, and the benefits of pairing intermittent fasting with various mindfulness techniques, such as meditation.